Sanofi SA (EPA:SAN) has been assigned a €81.00 ($96.43) target price by stock analysts at HSBC Holdings plc in a research note issued to investors on Wednesday. The firm presently has a “neutral” rating on the stock.

Other equities research analysts have also recently issued reports about the company. Morgan Stanley set a €91.00 ($108.33) target price on Sanofi SA and gave the company a “buy” rating in a research report on Tuesday, June 6th. Deutsche Bank AG set a €96.00 ($114.29) target price on Sanofi SA and gave the company a “buy” rating in a research report on Tuesday, May 2nd. Credit Suisse Group set a €95.00 ($113.10) target price on Sanofi SA and gave the company a “buy” rating in a research report on Tuesday, July 4th. Kepler Capital Markets set a €89.00 ($105.95) target price on Sanofi SA and gave the company a “buy” rating in a research report on Wednesday, July 26th. Finally, UBS AG set a €82.00 ($97.62) target price on Sanofi SA and gave the company a “neutral” rating in a research report on Wednesday, June 14th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the company’s stock. Sanofi SA currently has an average rating of “Hold” and an average price target of €87.69 ($104.39).

Shares of Sanofi SA (EPA SAN) opened at 81.96 on Wednesday. The company’s 50-day moving average price is €25.48 and its 200-day moving average price is €25.74. Sanofi SA has a one year low of €62.50 and a one year high of €92.97. The stock has a market cap of €102.92 billion and a PE ratio of 11.43.

WARNING: “HSBC Holdings plc Analysts Give Sanofi SA (SAN) a €81.00 Price Target” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/30/hsbc-holdings-plc-analysts-give-sanofi-sa-san-a-81-00-price-target.html.

Sanofi SA Company Profile

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Stock Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related stocks with our FREE daily email newsletter.